The Future of Surgical Management of Inflammatory Bowel Disease

[1]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[2]  E. Loftus,et al.  Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? , 2007, Inflammatory bowel diseases.

[3]  A. Griffiths,et al.  Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? , 2007, Inflammatory bowel diseases.

[4]  E. Toth,et al.  Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[5]  Alastair Forbes,et al.  Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility , 2007, Nature Genetics.

[6]  R. Summers Novel and future medical management of inflammatory bowel disease. , 2007, The Surgical clinics of North America.

[7]  P. Banks,et al.  Section editor's commentary. The role of panca and asca in differentiating ulcerative colitis, Crohn's disease, and indeterminate colitis , 2007 .

[8]  Philippe Goyette,et al.  Molecular pathogenesis of inflammatory bowel disease: Genotypes, phenotypes and personalized medicine , 2007, Annals of medicine.

[9]  S. Targan,et al.  Recent understanding of IBD pathogenesis: Implications for future therapies , 2006, Inflammatory bowel diseases.

[10]  Judy H. Cho,et al.  Genetic advances in inflammatory bowel disease , 2006, Current treatment options in gastroenterology.

[11]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[12]  W. Koltun Editorial: Imaging and Robotics in Surgical Practice , 2005 .

[13]  R. Duerr,et al.  Innate Immune Receptor Genetic Polymorphisms in Pouchitis: Is CARD15 a Susceptibility Factor? , 2005, Inflammatory bowel diseases.

[14]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[15]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[16]  R. Macdermott Lack of current clinical value of serological testing in the evaluation of patients with IBD. , 1999, Inflammatory bowel diseases.

[17]  S. Targan The utility of ANCA and ASCA in inflammatory bowel disease. , 1999, Inflammatory bowel diseases.

[18]  P. Banks,et al.  The Role of pANCA and ASCA in Differentiating Ulcerative Colitis, Crohnʼs Disease, and Indeterminate Colitis , 1999 .

[19]  W. Koltun,et al.  Techniques of disease activity assessment in Crohn's disease , 2001 .